A recent study conducted by researchers at Mayo Clinic highlights a potential breakthrough in weight management for postmenopausal women suffering from obesity. The research indicates that women receiving menopausal hormone therapy alongside the medication tirzepatide lost approximately 35% more weight compared to those on tirzepatide alone. This study, which was published in The Lancet Obstetrics, Gynaecology, & Women’s Health, may offer new treatment options for many women who face challenges related to obesity and associated health risks following menopause.
Menopause often accelerates age-related weight gain and increases the likelihood of developing conditions such as overweight and obesity. These conditions are significant risk factors for various diseases, including cardiovascular diseases and type 2 diabetes. The natural decline of estrogen levels during menopause can also lead to changes in the body that may independently increase cardiovascular risks, complicating weight management efforts for many women.
Hormone therapy is frequently prescribed as an effective first-line treatment for managing menopausal symptoms, such as hot flashes and night sweats, which affect upwards of 75% of postmenopausal women. Previous research has indicated synergy between hormone therapy and some GLP-1-based obesity medications, such as semaglutide. However, no earlier studies have focused on the interaction between hormone therapy and tirzepatide specifically, underscoring the importance of this latest research.
To explore the relationship between hormone therapy and tirzepatide, the team reviewed data from 120 participants who were overweight or obese and were treated with tirzepatide for a minimum of 12 months. They compared the outcomes of women receiving tirzepatide in conjunction with hormone therapy to those who were not on hormone therapy but had similar demographic characteristics.
The results demonstrated a notable difference in weight loss outcomes. Women utilizing menopausal hormone therapy alongside tirzepatide lost about 35% more weight compared to those receiving tirzepatide alone. However, the study's observational nature implies that a direct causal relationship cannot be established. According to Dr. Maria Daniela Hurtado Andrade, a senior author of the study, it is essential to consider that women using hormone therapy might already be following healthier lifestyle choices or may experience improvements in sleep and overall quality of life, potentially contributing to greater weight-loss success.
Despite the observational study's limitations, the findings suggest a clinically significant difference warranting further investigation. Dr. Regina Castaneda, the first author, emphasizes the need for future studies that can more systematically evaluate the interactions between GLP-1-based obesity medications and hormone therapy. Preclinical data hint at a possible synergy, where estrogen may amplify the appetite-suppressing effects of GLP-1 medications. Plans are underway to conduct a clinical trial that would examine not only weight loss outcomes but also whether hormone therapy could enhance the effects of these medications on cardiometabolic health measures.
The results of this study could significantly alter the landscape of treatment for millions of postmenopausal women, bringing forth new, evidence-based strategies aimed at mitigating cardiometabolic risks associated with obesity. Should future research validate these findings, it could lead to more personalized and effective approaches to managing weight and related health challenges in this population.
Personalise this feed
Your specialty. Your sources. Your digest.
All set up in under 2 minutes.
Personalise this feed
Your specialty. Your sources. Your digest.
All set up in under 2 minutes.